Skip to main content
Evidence Snapshot

Fatty acid-binding protein, liver

CHEMBL5738 SINGLE PROTEIN Rattus norvegicus
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:47Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5738
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Fatty acid-binding protein, liver as ChEMBL target CHEMBL5738, mapped to UniProt P02692. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Fatty acid-binding protein, liver
SINGLE PROTEIN · Rattus norvegicus
As of 2026-09-13
ChEMBL target ID
CHEMBL5738
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P02692
Fatty acid-binding protein, liver
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Fatty acid-binding protein, liver matters

As of 2026-09-13

Fatty acid-binding protein, liver is reviewed as Fatty acid-binding protein, liver (UniProt P02692); the current evidence base includes 18 approved drugs, 22 compounds, and 20 assays, with lead potency reaching pChEMBL 7.8.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 18 approved drugs, 22 compounds, and 20 assays for this target. The dominant activity type is KD. CHEMBL672 is the current potency anchor at pChEMBL 7.8.

Use CHEMBL672 as the tractability anchor when discussing potency (pChEMBL 7.8).

Activity source · ChEMBL 36 via Core Engine
18 approved pChEMBL 7.8
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Fatty acid-binding protein, liver matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P02692, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

22
Total Compounds
20
Total Assays
18
Approved Drugs
KI: 37.0, KD: 40.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL672
 7.8 Kd Approved
No preferred name
CHEMBL672
 7.6 Ki Approved
No preferred name
CHEMBL103
 7.6 Ki Approved
No preferred name
CHEMBL981
 7.0 Kd Approved
No preferred name
CHEMBL8659
 6.8 Ki Clinical

Approved Drugs

Structure Compound First Approval
FENOFIBRIC ACID
CHEMBL981
 2008
FENOFIBRATE
CHEMBL672
 1993
MECLOFENAMIC ACID
CHEMBL509
 1980
PROGESTERONE
CHEMBL103
 1976
DIAZEPAM
CHEMBL12
 1963
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:47Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5738